ES2208571T3 - Utilizacion del acido 2-metil-tiazolidina-2,4-dicarboxilico y/o de sus sales fisiologicamente compatibles, como agente anticanceroso. - Google Patents
Utilizacion del acido 2-metil-tiazolidina-2,4-dicarboxilico y/o de sus sales fisiologicamente compatibles, como agente anticanceroso.Info
- Publication number
- ES2208571T3 ES2208571T3 ES01913699T ES01913699T ES2208571T3 ES 2208571 T3 ES2208571 T3 ES 2208571T3 ES 01913699 T ES01913699 T ES 01913699T ES 01913699 T ES01913699 T ES 01913699T ES 2208571 T3 ES2208571 T3 ES 2208571T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- thiazolidine
- dicarboxylic
- cysteine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title claims description 30
- 239000003795 chemical substances by application Substances 0.000 title claims description 10
- JCAKCGQZNBEITC-UHFFFAOYSA-N 2-methyl-1,3-thiazolidine-2,4-dicarboxylic acid Chemical compound OC(=O)C1(C)NC(C(O)=O)CS1 JCAKCGQZNBEITC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 239000000824 cytostatic agent Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000000857 drug effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 84
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 44
- 229960004308 acetylcysteine Drugs 0.000 description 44
- 229960003180 glutathione Drugs 0.000 description 41
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 34
- 108010024636 Glutathione Proteins 0.000 description 23
- 239000004201 L-cysteine Substances 0.000 description 17
- 235000013878 L-cysteine Nutrition 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 229940076788 pyruvate Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000007096 poisonous effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003548 thiazolidines Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- DQMLFUMEBNHPPB-UHFFFAOYSA-N 2-Methylthiazolidine Chemical compound CC1NCCS1 DQMLFUMEBNHPPB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical group [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Chemical group [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10008159 | 2000-02-15 | ||
| DE10008159A DE10008159B4 (de) | 2000-02-15 | 2000-02-15 | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2208571T3 true ES2208571T3 (es) | 2004-06-16 |
Family
ID=7631906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01913699T Expired - Lifetime ES2208571T3 (es) | 2000-02-15 | 2001-02-15 | Utilizacion del acido 2-metil-tiazolidina-2,4-dicarboxilico y/o de sus sales fisiologicamente compatibles, como agente anticanceroso. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6943185B2 (enExample) |
| EP (1) | EP1255538B1 (enExample) |
| JP (1) | JP2003522782A (enExample) |
| CN (1) | CN1400899A (enExample) |
| AT (1) | ATE252383T1 (enExample) |
| AU (1) | AU783933B2 (enExample) |
| CA (1) | CA2399709C (enExample) |
| DE (2) | DE10008159B4 (enExample) |
| EA (1) | EA004592B1 (enExample) |
| ES (1) | ES2208571T3 (enExample) |
| MX (1) | MXPA02007903A (enExample) |
| PL (1) | PL357179A1 (enExample) |
| PT (1) | PT1255538E (enExample) |
| TR (1) | TR200302134T4 (enExample) |
| WO (1) | WO2001060343A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050197406A1 (en) * | 1999-04-14 | 2005-09-08 | Li Chiang J. | Method of treatment of lung cancer |
| DE10008159B4 (de) * | 2000-02-15 | 2005-08-18 | Rudy Dr. Susilo | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
| CN101838218A (zh) * | 2002-02-28 | 2010-09-22 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
| WO2005021486A1 (ja) * | 2003-08-29 | 2005-03-10 | Japan Tobacco Inc. | エステル誘導体及びその医薬用途 |
| DE102004021658A1 (de) * | 2004-05-03 | 2005-12-01 | Rudy Dr. Susilo | Kombinationspräparate enthaltend 2-Methylthiazolidin-2,4-dicarbonsäure |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
| JP5439849B2 (ja) * | 2008-02-28 | 2014-03-12 | 味の素株式会社 | システイン誘導体 |
| JP5378713B2 (ja) * | 2008-06-19 | 2013-12-25 | 日本理化学薬品株式会社 | 外用組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19711053C2 (de) * | 1997-03-03 | 1999-09-02 | Rommelspacher | Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol |
| DE19711052C2 (de) * | 1997-03-03 | 1999-09-23 | Hans Rommelspacher | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum |
| DE10008159B4 (de) * | 2000-02-15 | 2005-08-18 | Rudy Dr. Susilo | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
-
2000
- 2000-02-15 DE DE10008159A patent/DE10008159B4/de not_active Expired - Fee Related
-
2001
- 2001-02-15 US US10/182,442 patent/US6943185B2/en not_active Expired - Fee Related
- 2001-02-15 CN CN01805095A patent/CN1400899A/zh active Pending
- 2001-02-15 ES ES01913699T patent/ES2208571T3/es not_active Expired - Lifetime
- 2001-02-15 TR TR2003/02134T patent/TR200302134T4/xx unknown
- 2001-02-15 AT AT01913699T patent/ATE252383T1/de not_active IP Right Cessation
- 2001-02-15 PT PT01913699T patent/PT1255538E/pt unknown
- 2001-02-15 PL PL01357179A patent/PL357179A1/xx not_active Application Discontinuation
- 2001-02-15 EP EP01913699A patent/EP1255538B1/de not_active Expired - Lifetime
- 2001-02-15 AU AU39190/01A patent/AU783933B2/en not_active Ceased
- 2001-02-15 EA EA200200853A patent/EA004592B1/ru not_active IP Right Cessation
- 2001-02-15 WO PCT/DE2001/000656 patent/WO2001060343A2/de not_active Ceased
- 2001-02-15 CA CA002399709A patent/CA2399709C/en not_active Expired - Fee Related
- 2001-02-15 MX MXPA02007903A patent/MXPA02007903A/es active IP Right Grant
- 2001-02-15 DE DE50100833T patent/DE50100833D1/de not_active Expired - Lifetime
- 2001-02-15 JP JP2001559441A patent/JP2003522782A/ja active Pending
-
2005
- 2005-04-29 US US11/117,569 patent/US20050187271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE252383T1 (de) | 2003-11-15 |
| EP1255538A2 (de) | 2002-11-13 |
| AU783933B2 (en) | 2005-12-22 |
| PT1255538E (pt) | 2004-03-31 |
| EA004592B1 (ru) | 2004-06-24 |
| DE50100833D1 (de) | 2003-11-27 |
| DE10008159A1 (de) | 2001-09-06 |
| MXPA02007903A (es) | 2004-09-10 |
| EA200200853A1 (ru) | 2003-02-27 |
| DE10008159B4 (de) | 2005-08-18 |
| US20050187271A1 (en) | 2005-08-25 |
| EP1255538B1 (de) | 2003-10-22 |
| CN1400899A (zh) | 2003-03-05 |
| PL357179A1 (en) | 2004-07-26 |
| WO2001060343A3 (de) | 2002-05-30 |
| TR200302134T4 (tr) | 2004-01-21 |
| WO2001060343A2 (de) | 2001-08-23 |
| AU3919001A (en) | 2001-08-27 |
| US6943185B2 (en) | 2005-09-13 |
| US20030149085A1 (en) | 2003-08-07 |
| JP2003522782A (ja) | 2003-07-29 |
| CA2399709A1 (en) | 2001-08-23 |
| CA2399709C (en) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Santini | Amifostine: chemotherapeutic and radiotherapeutic protective effects | |
| Varanda et al. | Radioprotection: mechanisms and radioprotective agents including honeybee venom | |
| ES2208571T3 (es) | Utilizacion del acido 2-metil-tiazolidina-2,4-dicarboxilico y/o de sus sales fisiologicamente compatibles, como agente anticanceroso. | |
| EP1323423B1 (en) | Combined preparation comprising a morpholinyl anthracycline derivative and a topoisomerase II inhibitor | |
| JP2019514962A (ja) | 癌治療のための組み合わせ療法 | |
| EP0820281B1 (en) | A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses | |
| CN102357100A (zh) | 抗肿瘤联合药物 | |
| JP2024054295A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| EP3449919B1 (en) | Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation | |
| ES2268764T3 (es) | Combinacion antitumoral de 1,4-dioxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platino. | |
| WO2008134528A1 (en) | Anti-cancer agent-hyaluronic acid conjugate compositions and methods | |
| de Araújo Herculano et al. | NMDA preconditioning protects against quinolinic acid-induced seizures via PKA, PI3K and MAPK/ERK signaling pathways | |
| TWI834868B (zh) | 難治性癌症之預防或治療用之醫藥組合物 | |
| Pal et al. | Highly Efficient Prodrugs: Design and Therapeutic Applications (A-Review). | |
| ES2284674T3 (es) | Combinacion de terapia anticancerosa a base de derivados de distamicina acriloil sustituidos y agentes alquilantes. | |
| JP2023050198A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| US20100104628A1 (en) | method of treating neuroblastoma | |
| RU2771953C1 (ru) | Способ лечения неоперабельного плоскоклеточного рака ротовой полости у кошек | |
| US6245815B1 (en) | Method of treating alcoholism and complications resulting therefrom | |
| US5998479A (en) | Method of treating adult respiratory syndrome | |
| JP2016017059A (ja) | 抗腫瘍性プロドラッグを含む組成物 | |
| RU2339376C2 (ru) | Противолейкозная и антибактериальная композиция | |
| RU2339386C1 (ru) | Средство, обладающее избирательным радио- и химиозащитным действием | |
| RU2236848C1 (ru) | Средство, уменьшающее токсичность противоопухолевых препаратов | |
| JPH02235813A (ja) | 抗腫瘍剤 |